Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
CSL pays $117M for option on phase 3 blood clotting specialist
CSL has moved quickly to spend some of the money freed up by recent cuts, securing an option to buy VarmX in return for $117 million upfront.
Nick Paul Taylor
Sep 16, 2025 4:31am
GE HealthCare to acquire brain MRI AI developer icometrix
Sep 10, 2025 11:45am
Novartis spends $1.4B for Tourmaline, CV med that wowed in ph. 2
Sep 9, 2025 4:28am
Senseonics to retake Eversense commercial control from Ascensia
Sep 5, 2025 2:00pm
Illumina begins rolling out protein analysis platform
Sep 3, 2025 2:30pm
Terumo inks $1.5B deal for liver transplant developer OrganOx
Aug 25, 2025 11:45am
